Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 19, 2026.

The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches

Dongwei Xu, Min Xu, Seogsong Jeong and 4 more

Frontiers in Pharmacology · 2019 · Review · CC BY

doi:10.3389/fphar.2018.01428

Abstract

Oxidative stress and inflammation are the most important pathogenic events in the development and progression of liver diseases. Nuclear erythroid 2-related factor 2 (Nrf2) is the master regulator of the cellular protection via induction of anti-inflammatory, antioxidant, and cyto-protective genes expression. Multiple studies have shown that activation or suppression of this transcriptional factor significantly affect progression of liver diseases. Comprehensive understanding the roles of Nrf2 activation/expression and the outcomes of its activators/inhibitors are indispensable for defining the mechanisms and therapeutic strategies against liver diseases. In this current review, we discussed recent advances in the function and principal mechanisms by regulating Nrf2 in liver diseases, including acute liver failure, hepatic ischemia-reperfusion injury, alcoholic liver disease, viral hepatitis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and hepatocellular carcinoma.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Oxidative stress and inflammation are the most important pathogenic events in liver diseases. During liver injuries, the unregulated production of free radicals and/or ROS leads to damage of important biomolecules and cells and generation of proinflammatory genes. Antioxidant and anti-inflammatory therapy has been considered to be beneficial in liver diseases. Nrf2 is the master regulator of the primary means of cellular defense through mediation of antioxidant response, anti-inflammatory and cytoprotective properties, and dysregulation of Nrf2 activity has been revealed to correlated with the development of chronic inflammatory diseases. The protective effects of Nrf2 signaling pathway has been identified in a number of disease models, including acute kidney, lung or neurons injury, emphysema, and sepsis. Accumulating evidence also has implicated this transcription factor in various liver diseases, including acute hepatoxicity, NAFLD, NASH, ALD, DILI, viral hepatitis, liver fibrosis, hepatic IRI, and primary hepatic malignancies. Under acute and chronic oxidative stress and inflammatory conditions, Nrf2 is activated and prevents oxidative and inflammatory diseases by modulating genes expression of cytoprotective proteins and enzymes, which decreases ROS levels, inflammation, and cell death. However, the function of Nrf2 is not always protective in diseases, recent studies have identified that the gene expression of Nrf2 was associated with the pathogenesis, progression, and metastasis of cancer, resistance to cancer therapy, and the regulation of cancer cells metabolism, thereby suggesting that Nrf2 is a pleiotropic transcriptional factor. In this review, we summarized up-to-date studies in the understanding of the roles and mechanisms of Nrf2 and the therapeutic approaches by targeting Nrf2 in liver diseases.

Activation of Nrf2 Attenuates Acute Liver Injury

Study has shown that activation of Nrf2 attenuates acute liver injury. compared serum ALT, LDH, hepatic hemorrhage, and necrosis levels between Nrf2-null and Nrf2-enhanced mice in cadmium-induced acute liver injury mice model; they found that Nrf2-enhanced mice were associated with lower ALT and LDH levels and with fewer morphological alterations. The mRNA levels of cytoprotective genes, including sulfiredoxin-1, glutamate-cysteine ligase, and glutathione peroxidase-2 were expressed only in Nrf2-enhanced mice, suggesting that Nrf2 activation prevents oxidative stress and acute liver injury through modulation of antioxidant defense-associated genes (Figure 1). Subsequently, the protective effects of Nrf2 was tested in LPS and D-GalN-induced liver injury mouse models by treatment with mangiferin, which could upregulate the gene expression of Nrf2 in a dose-dependent manner. Mangiferin treatment suppressed serum levels of ALT, AST, IL-1β, TNF-α, and ROS levels, adding evidences that activation of Nrf2 pathway protects against acute liver injury. Biochanin A, morin, curcumin, andrographolide, oxymatrine, and madecassoside were also found to play a protective role via activation of Nrf2 in LPS and D-GalN-induced acute liver injury in mice. In addition, the antioxidant pathway of Nrf2 was further tested and found to be effective in carbon tetrachloride-induced and acetaminophen-induced mouse acute liver injury models. The role of Nrf2 in hepatic IRI was also identified by several studies. showed that the Keap1–Nrf2 complex could alleviate oxidative injury in mouse orthotopic liver transplantation through Keap1 signaling (Figure 1). The protective effects were identified by limiting hepatic inflammatory responses and hepatocellular necrosis. Recently, our research identified cytoprotective effects of CDDO-Im, a potent activator of the Nrf2 pathway, in hepatic IRI, through inducing Nrf2 target gene HO-1 expression leads to enhanced autophagy in hepatocytes, which results in increased clearance of damaged mitochondria, reduced mtDNA release and ROS production leading to reductions in DAMP release-induced inflammatory responses and subsequent secondary hepatocyte injury. Despite accumulating evidences, Nrf2-based treatment is yet to enter clinical trials in the USA 1 for patients with acute liver failure.

Activation of Nrf2 Ameliorates Alcoholic Liver Disease

Alcohol consumption has been revealed to be significantly associated with the development and progression of liver diseases over decades. Alcohol metabolism in the liver includes ethanol oxidation by alcohol dehydrogenase in hepatocytes and microsomal oxidation promoted by CYP2E1. Alcohol dehydrogenase-associated ethanol metabolism results in acetaldehyde, which gives rise to some downstream effects, such as depletion of glutathione, lipid peroxidation, and generation of ROS. In addition, the dysregulation of antioxidant glutathione by Nrf2-dependent regulation was found to contribute to the development of ALD by providing pathological conditions, whereas the Nrf2-mediated antioxidant response provided protection against alcohol-induced oxidative stress by regulating glutathione metabolism. Furthermore, the oxidative stress-induced upregulation of Nrf2 is considered to positively modulate expression of VLDLR, which contributes to ALD.

In ethanol-exposed mice, the role of Nrf2-induced antioxidant factors was first tested by the Nrf2 inducer D3T. Upregulation of Nrf2 by D3T treatment has significantly decreased generation of ethanol-induced ROS and apoptosis, which indicated that the activation of Nrf2 could diminish ethanol-induced apoptosis and ameliorate the disease status. Moreover, verified that Nrf2-mediated cytoprotective enzymes could ameliorate alcohol-induced liver steatosis both in in vivo and in vitro models. They further administered sulforaphane, which is an activator of Nrf2 and present in considerable quantities in brassica vegetables including broccoli, cabbage, and kale, and found it to be effective in improving alcohol-induced liver steatosis (Figure 2). Furthermore, recent advances indicated that activation of the Nrf2 pathway was protective in alcohol-induced liver fibrosis and hepatotoxicity, whereas knockdown of Nrf2 was associated with enhanced alcohol-induced hepatocyte necroptosis. By contrast, a more recent study demonstrated that ethyl pyruvate, which has multi-effects including antibacterial, anti-inflammatory, antiviral, vasodilatory, antioxidant, and antiapoptotic effects, decreases ALT, AST, hepatic morphological changes, triglycerides, free fatty acids, and the expression of proinflammatory factors and increases the expression of anti-inflammatory factors and peroxisome proliferator-activated receptor-α mRNA which through downregulation of the ROS–Nrf2 signaling pathway, thereby alleviating ALD in mice. Taken together, these evidences showed that Nrf2 activation plays essential protective role in the development of ALD and that simultaneous downregulation of Nrf2 with ROS and VLDLR may also be effective in the amelioration of ALD (Figure 2). Further studies are required to demonstrate the extent of amelioration between upregulation and downregulation of Nrf2 when ROS and VLDLR expression levels are downregulated in ALD.

Protective Effects of Nrf2 on Viral Hepatitis-Infected Cells Against Oxidative Damage

Oxidative stress has been shown to be implicated in viral hepatitis-associated liver diseases, including HBV and HCV infections. A previous study indicated that HCV could mediate the phosphorylation and activation of Nrf2, which was regulated by the mitogen-activated protein kinases. The authors further suggested that the activation of Nrf2-derived survival of HCV-infected cells may provide favorable circumstances for carcinogenesis. Another study showed that the inhibition of Nrf2 and antioxidant response elements is regulated by the core proteins of HCV-replicating cell-triggered delocalization of small Maf proteins, which were bound to NS proteins NS3, thus reducing the expression of cytoprotective genes. From the authors’ point of view, inhibition of Nrf2 and antioxidant response element-regulated genes may contribute to HCV-associated pathogenesis due to impaired induction of reactive oxygen intermediates caused by cytoprotective genes, which giving rise to host cell DNA damage and promoting the genetic variability of the viral genome. Moreover, found that the antioxidant-protective Nrf2/antioxidant response element pathway is activated by HCV proteins, including core, E1, E2, NS5A, and NS4B, in an ROS-dependent and -independent manners (Figure 3). In addition, a strong upregulation of the antioxidant-protective system was modulated in the earliest stage, indicating that Nrf2 is activated to protect against HCV-induced oxidative stress in the acute stage of HCV infection. In addition, replication of HCV has been reported to be suppressed by Nrf2-mediated heme oxygenase-1 (HO-1) inducible factor, which is a phytocompound isolated from Lindera erythrocarpa Makino fruits (lucidone), and a quinone methide triterpene isolated from Tripterygium wilfordii root extract (celastrol). Furthermore, an in vitro cell line study from Japan found that knockdown of Nrf2 significantly reduced HCV infection and steatosis. Most recently, the authors further confirmed that an Nrf2 inhibitor (brusatol) had anti-HCV effects in vitro (Figure 3).

Hepatitis B virus infection, which causes acute or chronic liver inflammation and contributes to the development of HCC, has been shown to induce activation of Nrf2 and antioxidative response elements in vivo and in vitro by HBV-regulatory proteins, including HBx and large surface proteins, via c-Raf and mitogen-activated protein kinase. In addition, the HBx protein-mediated activation of Nrf2 has been introduced to trigger the upregulation of glucose-6-phosphate dehydrogenase, thereby reprogramming metabolism of glucose, and may participate in the development of HCC. Therefore, Nrf2 is not only a crucial factor that is activated to defend against viral hepatitis-induced oxidative stress but also a protective factor that is involved in the survival of viral hepatitis-infected cells and may contribute to hepatocarcinogenesis.

Protective Impact of Nrf2 in Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease is a progressive disease arising from the accumulation of lipids in hepatocytes and has an increasing incidence worldwide. Approximately one-third of patients with NAFLD progress to severe NASH, which is linked with inflammation and cirrhosis. Recent studies indicated that ROS and electrophiles are associated with the pathogenesis of NASH; thus, induction of Nrf2 seemed to be promising in the prevention and treatment of NAFLD., explored the therapeutic impact of Nrf2 activation by using osteocalcin, and found that it could improve NAFLD by ameliorating oxidative stress and inhibiting the JNK pathway, which is an important pathway involved in the pathogenesis of NAFLD. A recent study demonstrated that scutellarin, a flavonoid glycoside that has an antioxidative stress effect, significantly reduced blood lipid levels and enhanced the antioxidative capacity by activating PPARγ and its coactivator-1α, Nrf2, HO-1, GST, and NQO1, and suppressing nuclear factor κB and Keap1 at the mRNA and protein levels, thus ameliorating NAFLD (Figure 4). In addition, a modulator of PPARγ, apigenin, was also revealed to attenuate NAFLD by Nrf2-associated regulation of oxidative stress and hepatocyte lipid metabolism. Moreover, for the prevention of NAFLD, scutellarin, which is a natural drug with active components of breviscapine, was shown to be effective by enhancing the Nrf2-mediated antioxidant system in high-fat diet- and chronic stress-subjected rats.

Nuclear erythroid 2-related factor 2 has been found to be a key regulator in the protection against NASH. By contrast, loss of Nrf2 or deletion of Nrf2 has been found to cause benign steatosis to develop into NASH and contribute to exacerbation of disease status. indicated that overactivation of Nrf2 suppressed the hepatocyte-specific c-met deletion (an accelerative factor for NASH)-induced deleterious impact on the progression of NASH and suggested that Nrf2 repaired liver damage in hepatocyte-specific c-met-deficient mice via maintaining balance in cellular redox homeostasis. To date, green tea extract and ezetimibe (an inhibitor of Niemann-Pick-C1-Like 1) have been revealed to promote the protective impact of Nrf2 against lipid accumulation and the inflammatory response during NASH (Figure 4). However, Nrf2-associated therapeutic approaches for NASH remain to be implemented in a real-world clinical manner in the near future.

Nrf2 in Primary Liver Cancer

Hepatocellular carcinoma is the most common primary liver cancer, accounting for more than 80% of all hepatic malignancies, with molecular alterations in HCC arising in the very early stage of carcinogenesis. Among the changes, activation of Nrf2 was found to be the prominent pathway that contributes to the progression of preneoplastic lesion to malignancy, which was confirmed by in vivo detection of the inhibition of the Nrf2 pathway that accompanied the regression of cytokeratin 19-positive nodules. The persistent activation of this transcription factor was found to be associated with the accumulation of p62, thus participating in the development of HCC. This finding was further supported by who confirmed the promotive impact of p62 in HCV-positive HCC through Nrf2-dependent metabolic reprogramming. In addition, Nrf2 was also found to participate in protection of HCC cells by facilitating the survival response of FGF19 to endoplasmic reticulum stress (Figure 5). Thus, advances were made to regulate the Nrf2 pathway in HCC, including identification of miR-340, miR-144, camptothecin, and valproic acid, which were revealed to be effective in suppressing the Nrf2-dependent pathway, thereby sensitizing HCC cells to anticancer treatments (Figure 5). Moreover, indazolo[3,2-b]quinazolinones were revealed to attack HCC cells by suppressing Nrf2/antioxidative response elements and inducing mitochondrial-dependent apoptosis simultaneously. In a clinical retrospective study, patients with high expression levels of Nrf2 (n = 48) had significantly reduced overall (median, 13.87 months) and disease-free survival (median, 11.24 months) compared with patients with low expression levels of Nrf2 (n = 17), who exhibited median overall survival of 30.40 months and disease-free survival of 24.43 months (P < 0.01). The relative risk of high Nrf2 levels in overall survival was 5.96 with 95% confidence interval of 2.46–14.69 (P < 0.01). However, regarding the sample size and retrospective nature, a large-sized prospective clinical study is required to confirm the prognostic impact of Nrf2 in patients with HCC.

Conclusion

In this review, we briefly summarized the biology characteristics of Nrf2 pathway and discussed the potential therapeutic applications of targeting Nrf2 in liver diseases. To date, there are currently few pharmacological options available to prevent or treat liver diseases. Recently, in clinical trial, NGM282, an engineered FGF19 analog, could significantly reduce liver fat content in patients with NASH and remarkably improve ALP and transaminase levels in patients with PBC. The small molecule PRI-724 also identified the anti-fibrotic effects in a phase 1 trial in patients with HCV cirrhosis.

A link between liver diseases and oxidative stress is indispensable. The Nrf2 antioxidant pathway is activated to protect the liver by modulating defensive genes, which even protect viral hepatitis-infected cells and HCC cells. A number of preclinical studies have detected regulatory factors for Nrf2; however, further identification of Nrf2 activators for liver injury/failure and Nrf2 inhibitors for viral hepatitis, and HCC is promising for the establishment of extensive and effective approaches to improve the prognosis of liver diseases. Regarding the great potential of this transcription factor, there is an unmet need for prospective clinical trials to explore the therapeutic impact of Nrf2 regulation in patients with liver diseases.

Author Contributions

DX and MX wrote the manuscript. SJ and YQ wrote some part of the manuscript and made language retouching for our manuscript. HW revised the manuscript. QX and XK designed and revised the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 88

  1. 1.

    Alam J. Stewart D. Touchard C. Boinapally S. Choi A. M. Cook J. L. (1999 ). Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 274 26071–26078.

    Not in our library10.1074/jbc.274.37.26071

  2. 2.

    Bae S. H. Sung S. H. Cho E. J. Lee S. K. Lee H. E. Woo H. A. (2011 ). Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol-induced oxidative injury in mouse liver. Hepatology (Baltimore, Md) 53 945–953.

    Not in our library10.1002/hep.24104

  3. 3.

    Bataille A. M. Manautou J. E. (2012 ). Nrf2: a potential target for new therapeutics in liver disease. Clin. Pharmacol. Ther. 92 340–348.

    Not in our library10.1038/clpt.2012.110

  4. 4.

    Bellezza I. Giambanco I. Minelli A. Donato R. (2018 ). Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim. Biophys. Acta 1865721–733.

    Not in our library10.1016/j.bbamcr.2018.02.010

  5. 5.
    Increased oxidative stress associated with the severity of the liver disease in various forms of hepatitis B virus infection · 2005
    No notice
  6. 6.

    Burdette D. Olivarez M. Waris G. (2010 ). Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway. J. Gen. Virol. 91 681–690.

    Not in our library10.1099/vir.0.014340-0

  7. 7.

    Cao M. Wang H. Guo L. Yang S. Liu C. Khor T. O. (2017 ). Dibenzoylmethane protects against CCl4-induced acute liver injury by activating Nrf2 via JNK, AMPK, and calcium signaling. AAPS J. 19 1703–1714.

    Not in our library10.1208/s12248-017-0133-1

  8. 8.

    Carvajal-Yepes M. Himmelsbach K. Schaedler S. Ploen D. Krause J. Ludwig L. (2011 ). Hepatitis C virus impairs the induction of cytoprotective Nrf2 target genes by delocalization of small Maf proteins. J. Biol. Chem. 286 8941–8951.

    Not in our library10.1074/jbc.m110.186684

  9. 9.
    The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism · 2015
    No notice
  10. 10.

    Chen F. Wang H. Zhu J. Zhao R. Xue P. Zhang Q. (2017 ). Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs. Br. J. Cancer 117 1495–1506.

    Not in our library10.1038/bjc.2017.317

  11. 11.

    Chen W. C. Wang S. Y. Chiu C. C. Tseng C. K. Lin C. K. Wang H. C. (2013 ). Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction. Antimicrob. Agents Chemother. 57 1180–1191.

    Not in our library10.1128/aac.02053-12

  12. 12.

    Chowdhry S. Nazmy M. H. Meakin P. J. Dinkova-Kostova A. T. Walsh S. V. Tsujita T. (2010 ). Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic. Biol. Med. 48 357–371.

    Not in our library10.1016/j.freeradbiomed.2009.11.007

  13. 13.

    Dey A. Cederbaum A. I. (2006 ). Alcohol and oxidative liver injury. Hepatology (Baltimore, Md) 43 S63–S74.

    Not in our library10.1002/hep.20957

  14. 14.

    Dietrich P. Hellerbrand C. (2014 ). Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract. Res. Clin. Gastroenterol. 28 637–653.

    Not in our library10.1016/j.bpg.2014.07.008

  15. 15.

    Dong J. Sulik K. K. Chen S. Y. (2008 ). Nrf2-mediated transcriptional induction of antioxidant response in mouse embryos exposed to ethanol in vivo: implications for the prevention of fetal alcohol spectrum disorders. Antioxid. Redox Signal. 10 2023–2033.

    Not in our library10.1089/ars.2007.2019

  16. 16.

    Du J. Zhang M. Lu J. Zhang X. Xiong Q. Xu Y. (2016 ). Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK. Endocrine 53 701–709.

    Not in our library10.1007/s12020-016-0926-5

  17. 17.

    Fan H. Ma X. Lin P. Kang Q. Zhao Z. Wang L. (2017 ). Scutellarin prevents nonalcoholic fatty liver disease (NAFLD) and hyperlipidemia via PI3K/AKT-dependent activation of nuclear factor (erythroid-derived 2)-like 2 (nrf2) in Rats. Med. Sci. Monit. 23 5599–5612.

    Not in our library10.12659/msm.907530

  18. 18.

    Fawcett T. W. Martindale J. L. Guyton K. Z. Hai T. Holbrook N. J. (1999 ). Complexes containing activating transcription factor (ATF)/cAMP-responsive-element-binding protein (CREB) interact with the CCAAT/enhancer-binding protein (C/EBP)-ATF composite site to regulate Gadd153 expression during the stress response. Biochem. J. 339(Pt 1), 135–141.

    Not in our library

  19. 19.

    Feng X. Yu W. Li X. Zhou F. Zhang W. Shen Q. (2017 ). Apigenin, a modulator of PPARgamma, attenuates HFD-induced NAFLD by regulating hepatocyte lipid metabolism and oxidative stress via Nrf2 activation. Biochem. Pharmacol. 136 136–149.

    Not in our library10.1016/j.bcp.2017.04.014

  20. 20.

    Forner A. Reig M. Bruix J. (2018 ). Hepatocellular carcinoma. Lancet 391 1301–1314.

    Not in our library10.1016/s0140-6736(18)30010-2

  21. 21.
    Brg1-mediated Nrf2/HO-1 pathway activation alleviates hepatic ischemia–reperfusion injury · 2017
    No notice
  22. 22.

    Gupte A. A. Lyon C. J. Hsueh W. A. (2013 ). Nuclear factor (erythroid-derived 2)-like-2 factor (Nrf2), a key regulator of the antioxidant response to protect against atherosclerosis and nonalcoholic steatohepatitis. Curr. Diabetes Rep. 13 362–371.

    Not in our library10.1007/s11892-013-0372-1

  23. 23.

    Harding H. P. Zhang Y. Bertolotti A. Zeng H. Ron D. (2000 ). Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol. Cell 5 897–904.

    Not in our library10.1016/s1097-2765(00)80330-5

  24. 24.

    Harrison S. A. Rinella M. E. Abdelmalek M. F. Trotter J. F. Paredes A. H. Arnold H. L. (2018 ). NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 391 1174–1185.

    Not in our library10.1016/s0140-6736(18)30474-4

  25. 25.

    Harvey C. J. Thimmulappa R. K. Singh A. Blake D. J. Ling G. Wakabayashi N. (2009 ). Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic. Biol. Med. 46 443–453.

    Not in our library10.1016/j.freeradbiomed.2008.10.040

  26. 26.
    The Crosstalk between Nrf2 and Inflammasomes · 2018
    No notice
  27. 27.

    Hildt E. Munz B. Saher G. Reifenberg K. Hofschneider P. H. (2002 ). The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J. 21 525–535.

    Not in our library10.1093/emboj/21.4.525

  28. 28.

    Huang Y. J. Chen P. Lee C. Y. Yang S. Y. Lin M. T. Lee H. S. (2016 ). Protection against acetaminophen-induced acute liver failure by omentum adipose tissue derived stem cells through the mediation of Nrf2 and cytochrome P450 expression. J. Biomed. Sci. 23:5.

    Not in our library10.1186/s12929-016-0231-x

  29. 29.

    Inami Y. Waguri S. Sakamoto A. Kouno T. Nakada K. Hino O. (2011 ). Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J. Cell Biol. 193 275–284.

    Not in our library10.1083/jcb.201102031

  30. 30.
    HCV and Oxidative Stress in the Liver · 2013
    No notice
  31. 31.
    Hepatitis C Virus Proteins Activate NRF2/ARE Pathway by Distinct ROS-Dependent and Independent Mechanisms in HUH7 Cells · 2011
    No notice
  32. 32.

    Karin M. Dhar D. (2016 ). Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2. Carcinogenesis 37 541–546.

    Not in our library10.1093/carcin/bgw060

  33. 33.

    Ke B. Shen X. D. Zhang Y. Ji H. Gao F. Yue S. (2013 ). KEAP1-NRF2 complex in ischemia-induced hepatocellular damage of mouse liver transplants. J. Hepatol. 59 1200–1207.

    Not in our library10.1016/j.jhep.2013.07.016

  34. 34.

    Klaassen C. D. Reisman S. A. (2010 ). Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. Toxicol. Appl. Pharmacol. 244 57–65.

    Not in our library10.1016/j.taap.2010.01.013

  35. 35.

    Kudo M. Finn R. S. Qin S. Han K. H. Ikeda K. Piscaglia F. (2018 ). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391 1163–1173.

    Not in our library10.1016/s0140-6736(18)30207-1

  36. 36.

    Kudoh K. Uchinami H. Yoshioka M. Seki E. Yamamoto Y. (2014 ). Nrf2 activation protects the liver from ischemia/reperfusion injury in mice. Ann. Surg. 260 118–127.

    Not in our library10.1097/sla.0000000000000287

  37. 37.

    Lee D. H. Han D. H. Nam K. T. Park J. S. Kim S. H. Lee M. (2016 ). Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. Free Radic. Biol. Med. 99 520–532.

    Not in our library10.1016/j.freeradbiomed.2016.09.009

  38. 38.

    Li J. Sapper T. N. Mah E. Rudraiah S. Schill K. E. Chitchumroonchokchai C. (2016 ). Green tea extract provides extensive Nrf2-independent protection against lipid accumulation and NFkappaB pro- inflammatory responses during nonalcoholic steatohepatitis in mice fed a high-fat diet. Mol. Nutr. Food Res. 60 858–870.

    Not in our library10.1002/mnfr.201500814

  39. 39.
    Hepatitis B virus stimulates G6PD expression through HBx-mediated Nrf2 activation · 2015
    No notice
  40. 40.

    Liu M. Reddy N. M. Higbee E. M. Potteti H. R. Noel S. Racusen L. (2014 ). The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice. Kid. Int. 85 134–141.

    Not in our library10.1038/ki.2013.357

  41. 41.

    Liu X. Wang T. Liu X. Cai L. Qi J. Zhang P. (2016 ). Biochanin A protects lipopolysaccharide/D-galactosamine-induced acute liver injury in mice by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. Int. Immunopharmacol. 38 324–331.

    Not in our library10.1016/j.intimp.2016.06.009

  42. 42.

    Lu C. Xu W. Zhang F. Shao J. Zheng S. (2016 ). Nrf2 knockdown disrupts the protective effect of curcumin on alcohol-induced hepatocyte necroptosis. Mol. Pharm. 13 4043–4053.

    Not in our library10.1021/acs.molpharmaceut.6b00562

  43. 43.

    Lu S. C. (2013 ). Glutathione synthesis. Biochim. Biophys. Acta 2013 3143–3153.

    Not in our library10.1016/j.bbagen.2012.09.008

  44. 44.

    Mayo M. J. Wigg A. J. Leggett B. A. Arnold H. Thompson A. J. Weltman M. (2018 ). NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatol. Commun. 2 1037–1050.

    Not in our library10.1002/hep4.1209

  45. 45.

    Murakami Y. Sugiyama K. Ebinuma H. Nakamoto N. Ojiro K. Chu P. S. (2018 ). Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells. BMC Cancer 18:680.

    Not in our library10.1186/s12885-018-4588-y

  46. 46.

    Ni Y. H. Huo L. J. Li T. T. (2017 ). Antioxidant axis Nrf2-keap1-ARE in inhibition of alcoholic liver fibrosis by IL-22. World J. Gastroenterol. 23 2002–2011.

    Not in our library10.3748/wjg.v23.i11.2002

  47. 47.

    Pan C. W. Pan Z. Z. Hu J. J. Chen W. L. Zhou G. Y. Lin W. (2016 ). Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. Eur. J. Pharmacol. 770 85–91.

    Not in our library10.1016/j.ejphar.2015.12.006

  48. 48.

    Pan C. W. Yang S. X. Pan Z. Z. Zheng B. Wang J. Z. Lu G. R. (2017 ). Andrographolide ameliorates d-galactosamine/lipopolysaccharide-induced acute liver injury by activating Nrf2 signaling pathway. Oncotarget 8 41202–41210.

    Not in our library10.18632/oncotarget.17149

  49. 49.

    Peng X. Dai C. Liu Q. Li J. Qiu J. (2018 ). Curcumin attenuates on carbon tetrachloride-induced acute liver injury in mice via modulation of the Nrf2/HO-1 and TGF-beta1/Smad3 pathway. Molecules (Basel, Switzerland) 23:E215.

    Not in our library10.3390/molecules23010215

  50. 50.

    Petrelli A. Perra A. Cora D. Sulas P. Menegon S. Manca C. (2014 ). MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology (Baltimore, Md) 59228–241.

    Not in our library10.1002/hep.26616

  51. 51.

    Pitot H. C. (2007 ). Adventures in hepatocarcinogenesis. Annu. Rev. Pathol. 2 1–29.

    Not in our library10.1146/annurev.pathol.2.010506.092027

  52. 52.

    Ramadori P. Drescher H. Erschfeld S. Fragoulis A. Kensler T. W. Wruck C. J. (2017 ). Genetic Nrf2 overactivation inhibits the deleterious effects induced by hepatocyte-specific c-met deletion during the progression of NASH. Oxid. Med. Cell. Longev. 2017:3420286.

    Not in our library10.1155/2017/3420286

  53. 53.

    Rao J. Qian X. Li G. Pan X. Zhang C. Zhang F. (2015 ). ATF3-mediated NRF2/HO-1 signaling regulates TLR4 innate immune responses in mouse liver ischemia/reperfusion injury. Am. J. Transplant 15 76–87.

    Not in our library10.1111/ajt.12954

  54. 54.

    Reddy N. M. Suryanaraya V. Yates M. S. Kleeberger S. R. Hassoun P. M. Yamamoto M. (2009 ). The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice. Am. J. Respir. Crit. Care Med. 180 867–874.

    Not in our library10.1164/rccm.200905-0670oc

  55. 55.

    Rejitha S. Prathibha P. Indira M. (2015 ). Nrf2-mediated antioxidant response by ethanolic extract of Sida cordifolia provides protection against alcohol-induced oxidative stress in liver by upregulation of glutathione metabolism. Redox Rep. 20 75–80.

    Not in our library10.1179/1351000214y.0000000108

  56. 56.

    Rojo de la Vega M. Chapman E. Zhang D. D. (2018 ). NRF2 and the hallmarks of cancer. Cancer Cell 34 21–43.

    Not in our library10.1016/j.ccell.2018.03.022

  57. 57.
    p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming · 2016
    No notice
  58. 58.

    Satapathy S. K. Sanyal A. J. (2015 ). Epidemiology and natural history of nonalcoholic fatty liver disease. Semin. Liver Dis. 35 221–235.

    Not in our library10.1055/s-0035-1562943

  59. 59.

    Schaedler S. Krause J. Himmelsbach K. Carvajal-Yepes M. Lieder F. Klingel K. (2010 ). Hepatitis B virus induces expression of antioxidant response element-regulated genes by activation of Nrf2. J. Biol. Chem. 285 41074–41086.

    Not in our library10.1074/jbc.m110.145862

  60. 60.

    Shen F. Wang Z. Liu W. Liang Y. (2018a ). Ethyl pyruvate can alleviate alcoholic liver disease through inhibiting Nrf2 signaling pathway. Exp. Ther. Med. 15 4223–4228.

    Not in our library10.3892/etm.2018.5925

  61. 61.

    Shen Z. Wang Y. Su Z. Kou R. Xie K. Song F. (2018b ). Activation of p62-keap1-Nrf2 antioxidant pathway in the early stage of acetaminophen-induced acute liver injury in mice. Chem. Biol. Interact. 282 22–28.

    Not in our library10.1016/j.cbi.2018.01.008

  62. 62.

    Shepard B. D. Tuma D. J. Tuma P. L. (2010 ). Chronic ethanol consumption induces global hepatic protein hyperacetylation. Alcohol. Clin. Exp. Res. 34 280–291.

    Not in our library10.1111/j.1530-0277.2009.01091.x

  63. 63.

    Shi L. Chen Z. G. Wu L. L. Zheng J. J. Yang J. R. Chen X. F. (2014 ). miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Asian Pac J. Cancer Prev. 15 10439–10444.

    Not in our library10.7314/apjcp.2014.15.23.10439

  64. 64.

    Song X. Yin S. Huo Y. Liang M. Fan L. Ye M. (2015 ). Glycycoumarin ameliorates alcohol-induced hepatotoxicity via activation of Nrf2 and autophagy. Free Radic. Biol. Med. 89 135–146.

    Not in our library10.1016/j.freeradbiomed.2015.07.006

  65. 65.
    Prominent steatosis with hypermetabolism of the cell line permissive for years of infection with hepatitis C virus. · 2014
    Not checked
  66. 66.

    Sussan T. E. Rangasamy T. Blake D. J. Malhotra D. El-Haddad H. Bedja D. (2009 ). Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc. Natl. Acad. Sci. U.S.A. 106 250–255.

    Not in our library10.1073/pnas.0804333106

  67. 67.

    Tang W. Jiang Y. F. Ponnusamy M. Diallo M. (2014 ). Role of Nrf2 in chronic liver disease. World J. Gastroenterol. 20 13079–13087.

    Not in our library10.3748/wjg.v20.i36.13079

  68. 68.

    Tarantino G. Finelli C. (2013 ). Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. World J. Gastroenterol. 19 6735–6743.

    Not in our library10.3748/wjg.v19.i40.6735

  69. 69.

    Teng Y. Zhao H. Gao L. Zhang W. Shull A. Y. Shay C. (2017 ). FGF19 protects hepatocellular carcinoma cells against endoplasmic reticulum stress via activation of FGFR4-GSK3beta-Nrf2 signaling. Cancer Res. 77 6215–6225.

    Not in our library10.1158/0008-5472.can-17-2039

  70. 70.

    Thimmulappa R. K. Fuchs R. J. Malhotra D. Scollick C. Traore K. Bream J. H. (2007 ). Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxid. Redox Signal. 9 1963–1970.

    Not in our library10.1089/ars.2007.1745

  71. 71.

    Tian B. Lu Z. N. Guo X. L. (2018 ). Regulation and role of nuclear factor-E2-related factor 2 (Nrf2) in multidrug resistance of hepatocellular carcinoma. Chem. Biol. Interact. 280 70–76.

    Not in our library10.1016/j.cbi.2017.12.014

  72. 72.

    Tian Y. Li Z. Shen B. Zhang Q. Feng H. (2017 ). Protective effects of morin on lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting TLR4/NF-kappaB and activating Nrf2/HO-1 signaling pathways. Int. Immunopharmacol. 45 148–155.

    Not in our library10.1016/j.intimp.2017.02.010

  73. 73.

    Tseng C. K. Hsu S. P. Lin C. K. Wu Y. H. Lee J. C. Young K. C. (2017 ). Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK/Nrf2 pathway in human hepatoma cells. Antiv. Res. 146 191–200.

    Not in our library10.1016/j.antiviral.2017.09.010

  74. 74.
    Nrf2, the Master Regulator of Anti-Oxidative Responses · 2017
    No notice
  75. 75.

    Wang C. Cui Y. Li C. Zhang Y. Xu S. Li X. (2013 ). Nrf2 deletion causes “benign” simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet. Lipids Health Dis. 12:165.

    Not in our library10.1186/1476-511x-12-165

  76. 76.

    Wang W. Wu L. Li Q. Zhang Z. Xu L. Lin C. (2018 ). Madecassoside prevents acute liver failure in LPS/D-GalN-induced mice by inhibiting p38/NF-kappaB and activating Nrf2/HO-1 signaling. Biomed. Pharmacother. 1031137–1145.

    Not in our library10.1016/j.biopha.2018.04.162

  77. 77.

    Wang Y. Kou Y. Wang X. Cederbaum A. Wang R. (2014a ). Multifactorial comparative proteomic study of cytochrome P450 2E1 function in chronic alcohol administration. PLoS One 9:e92504.

    Not in our library10.1371/journal.pone.0092504

  78. 78.

    Wang Z. Dou X. Li S. Zhang X. Sun X. Zhou Z. (2014b ). Nuclear factor (erythroid-derived 2)-like 2 activation-induced hepatic very-low-density lipoprotein receptor overexpression in response to oxidative stress contributes to alcoholic liver disease in mice. Hepatology (Baltimore, Md) 59 1381–1392.

    Not in our library10.1002/hep.26912

  79. 79.

    Wu K. C. Liu J. J. Klaassen C. D. (2012 ). Nrf2 activation prevents cadmium-induced acute liver injury. Toxicol. Appl. Pharmacol. 263 14–20.

    Not in our library10.1016/j.taap.2012.05.017

  80. 80.

    Xie Y. L. Chu J. G. Jian X. M. Dong J. Z. Wang L. P. Li G. X. (2017 ). Curcumin attenuates lipopolysaccharide/d-galactosamine-induced acute liver injury by activating Nrf2 nuclear translocation and inhibiting NF-kB activation. Biomed. Pharmacother. 91 70–77.

    Not in our library10.1016/j.biopha.2017.04.070

  81. 81.

    Xu D. Chen L. Chen X. Wen Y. Yu C. Yao J. (2017 ). The triterpenoid CDDO-imidazolide ameliorates mouse liver ischemia-reperfusion injury through activating the Nrf2/HO-1 pathway enhanced autophagy. Cell Death Dis. 8:e2983.

    Not in our library10.1038/cddis.2017.386

  82. 82.

    Yu J. I. Choi C. Shin S. W. Son A. Lee G. H. Kim S. Y. (2017 ). Valproic acid sensitizes hepatocellular carcinoma cells to proton therapy by suppressing NRF2 activation. Sci. Rep. 7:14986.

    Not in our library10.1038/s41598-017-15165-3

  83. 83.

    Zhang F. Wang S. Zhang M. Weng Z. Li P. Gan Y. (2012 ). Pharmacological induction of heme oxygenase-1 by a triterpenoid protects neurons against ischemic injury. Stroke 43 1390–1397.

    Not in our library10.1161/strokeaha.111.647420

  84. 84.
    Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma · 2015
    No notice
  85. 85.

    Zhang X. Ji R. Sun H. Peng J. Ma X. Wang C. (2018 ). Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARgamma/PGC-1alpha-Nrf2 pathway. Free Radic. Res. 52 198–211.

    Not in our library10.1080/10715762.2017.1422602

  86. 86.

    Zhang Y. Qiao R. He D. Zhao Z. Yang S. Zou H. (2016 ). Indazolo[3,2-b]quinazolinones attack hepatocellular carcinoma Hep3B cells by inducing mitochondrial-dependent apoptosis and inhibition of Nrf2/ARE signaling pathway. Curr. Mol. Med. 16 820–828.

    Not in our library10.2174/1566524016666161128114444

  87. 87.

    Zhou R. Lin J. Wu D. (2014 ). Sulforaphane induces Nrf2 and protects against CYP2E1-dependent binge alcohol-induced liver steatosis. Biochim. Biophys. Acta 1840 209–218.

    Not in our library10.1016/j.bbagen.2013.09.018

  88. 88.

    Zhou S. Ye W. Zhang Y. Yu D. Shao Q. Liang J. (2016 ). miR-144 reverses chemoresistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Am. J. Transl. Res. 82992–3002.

    Not in our library

Cited by papers we hold 8

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.